Founded by Carlos Jorge Monteiro in 2006, the pharmaceutical company that leads the Acute Lymphoblastic Leukaemia (ALL) field in the Iberian Peninsula has been committed to introducing innovative therapies in various markets.
It was founded in 2006 with the aim of "investing in a differentiating project" based on innovation. Biojam Holding Group is a pharmaceutical group with Portuguese roots that has dedicated itself to the development of medicines in the field of rare diseases, but also to the creation of covid-19 diagnostic products.
His greatest achievement was leading the Iberian market in the treatment of Acute Lymphoblastic Leukaemia (ALL). Today, after rebranding the company in 2015, the founder has decided to dedicate himself to various business areas, having already launched innovative products in fields such as anaesthesiology, hospital pharmacy, women's health and oncology, among others.
Exame spoke to entrepreneur Carlos Jorge Monteiro to find out about the pharmaceutical company's journey, but above all his plans for the future.
Source: Exame
